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What test is the best for diagnosing
infectious mononucleosis?
E V I D E N C E - B A S E D A N SW E R
C L I N I C A L C O M M E N TA R Y
Tests for antibodies to Epstein-Barr viral
capsid antigen (EBVCA) or Epstein-Barr
nuclear antigen (EBNA) are the most sensi-
tive, are highly specific, and are also the
most expensive for diagnosing infectious
mononucleosis (strength of recommenda-
tion [SOR]: C, based on validating cohort
study). Heterophile antibody tests have simi-
lar specificity and are cheaper, but are less
sensitive in children or in adults during the
early days of the illness (SOR: C, based on
validating cohort study). The polymerase
chain reaction (PCR) assay for Epstein-Barr
virus DNA is more sensitive than the 
heterophile antibody test in children, is 
highly specific, but is also expensive (SOR:
C, based on validating cohort study). The
percentages of atypical lymphocytes and
total lymphocytes on a complete blood
count (CBC) provide another specific and
moderately sensitive, yet inexpensive, test
(SOR: C based on validating cohort study).
Initial testing with a CBC 
is a reasonable strategy
Diagnosis of infectious mononucleosis 
by currently available testing remains
somewhat problematic, especially early 
in the course of the illness. Initial testing
with a CBC—looking for atypical 
lymphocytes (which after several days
replace the early granulocytic response)
and a heterophile antibody titer—is a 
reasonable strategy.
Most testing for infectious mononucleo-
sis is antibody rather than antigen-related.
Thus, delayed or serial testing is more
accurate as it takes days to weeks for full
antibody response to develop. If the clinical
picture remains consistent with a mono-
nucleosis-like syndrome and serial EBV
testing is negative, then other illnesses such
as cytomegalovirus and toxoplasmosis
should be considered.
Robert Sheeler, MD
Mayo Clinic Rochester
z Evidence summary
EBV-specific antibody tests. A validating
cohort study assessed the sensitivity and
specificity of 6 commercial test kits for
detection of Epstein-Barr virus-specific
antibodies (EBVCA and EBNA). The
study compared antibody levels in 139
serum specimens from patients with recent
primary EBV infections (confirmed by both
a positive heterophile antibody test and an
EBV antibody pattern compatible with
recent infection) and in 40 specimens from
healthy normal controls. The average sensi-
tivity of the antibody tests was 97%
Most tests 
for infectious
mononucleosis are
antibody-related;
thus, delayed 
or serial testing 
is more accurate
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Comparison of various tests for infectious mononucleosis
TEST SN SP LR+ LR– COST
Patients with clinically 
suspected IM and:
Antibody to VCA or EBNA 97 (95-99) 94 (89-99) 16 0.03 $64–$232
Heterophile antibody— 87 (79-95) 91 (82-99) 9.7 0.14 $36–$64
latex agglutination
Heterophile antibody— 83 (71-95) 97 (94-99) 28 0.18 $36–$64
solid-phase immunoassay
Atypical lymphocytes $37–$50
(CBC with differential)
>10% 75 92 9.4 0.27
>20% 56 98 28 0.44
>40% 25 100 50 0.75
Total lymphocytes $20–$44
(peripheral smear)
>50% lymphocytes 66 84 4.1 0.40
>50% lymphocytes with 61 95 12 0.41
>10% atypical 
lymphocytes
PCR for EBV DNA 75 (62–78) 95.5 16.67 0.26 $64–$232
(79–99.8)
SN, sensitivity; SP, specificity; LR, likelihood ratio; IM, infectious mononucleosis; VCA, viral capsid antigen; EBNA, Epstein-
Barr nuclear antigen; CBC, complete blood count; PCR, polymerase chain reaction
(95%–99%) and average specificity was
94% (86%–100%).1
Heterophile antibody tests. Two vali-
dating cohort studies assessed the accuracy
of several commercially available test kits
for the detection of heterophile antibodies
(eg, “Mono spot” tests). The first com-
pared 6 kits using either a latex agglutina-
tion or a solid-phase assay against a “gold
standard” of serologic verification for 53
serum samples from primary EBV infec-
tion, 26 samples from EBV immune
patients, and 21 samples from healthy
donors.2 Serologic verification used
immunoflourescence to determine: the
absence of IgG but presence of IgM, the
presence of IgG but absence of IgM, or the
absence of both antibodies (respectively)
against EBVCA. The second study used a
similar method to test 6 more heterophile
kits using blood samples from 140
patients.1 The sensitivity of heterophile
antibody testing is lower in children under
12 (25%–50%) and early in the illness
(25% false-negative rate in first week).3
PCR assay for EBV DNA. Another vali-
dating cohort study evaluated PCR testing
for EBV DNA among children (average age
9 years, 4 months), 28 with infectious
mononucleosis, 25 who were EBV seroneg-
ative, and 26 who were seropositive.
Children with acute infectious mononucle-
osis were diagnosed by symptoms, >10%
atypical lymphocytes, and a positive het-
erophile antibody test. The PCR found a
sensitivity and specificity of 75% and 98%
at 1 week.4 Testing earlier, especially in chil-
dren, is expected to decrease the sensitivity
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due to the lower maturity of the immune
system response. 
Lymphocyte and atypical lymphocyte
count. A validating cohort study compared
peripheral blood samples in 181 patients
aged >16 years with a clinical diagnosis of
infectious mononucleosis confirmed by a
positive heterophile antibody test with
those from 181 similar patients with a neg-
ative test. An increased percentage of lym-
phocytes and atypical lymphocytes were
associated with higher sensitivity and
specificity for infectious mononucleosis.5
Recommendations from others
In the appropriate clinical situation, the
Centers for Disease Control and
Prevention recommends verifying the diag-
nosis of infectious mononucleosis with a
CBC and heterophile antibody test. If the
heterophile test result is negative, addition-
al testing such as EBV DNA tests may be
necessary.6
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